Scribe Therapeutics is a clinical-stage gene editing company developing next-generation CRISPR-based therapies for serious genetic diseases.
Company Info
Funding & Investor Relations
Filed S-1 July 2026
Upcoming Milestones & Key Dates
IPO expected
Clinical Development Pipeline
Recent News
Early-stage genetic medicines biotech Scribe Therapeutics signals IPO ambitions despite investor preference for de-risked late-stage assets. (Source: BioSpace, 2026-07-06)
Gene editing developer Scribe plots an IPO (BioPharma Dive.)
Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs — Endpoints News coverage of biopharma industry developments.
Leadership Team
Chief Executive Officer
Chief Financial Officer
Chief Medical Officer
Careers & Job Openings